logo
logo

Synchron Raises $75M Series C Led By Arch Venture Partners To Advance Endovascular Brain-Computer Interface

Dec 15, 2022over 2 years ago

Amount Raised

$75 Million

Round Type

series c

New YorkMedical Equipment Manufacturing

Investors

Id8 InvestmentsForepont Capital PartnersNeuro Technology InvestorsKhosla VenturesMoore Strategic VenturesAlumni VenturesArch Venture Partners

Description

Synchron, the endovascular brain-computer interface (BCI) company, announced today an oversubscribed $75 million Series C financing round led by ARCH Venture Partners. Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X join ARCH as new additional investors. Existing investors, including Khosla Ventures, NeuroTechnology Investors, METIS, Forepont Capital Partners, ID8 Investments, Shanda Group and University of Melbourne participated in the round. The Series C funding brings the total amount raised since inception to $145 million.

Company Information

Company

Synchron

Location

New York, United States

About

Since 2012, we have been developing a solution that avoids the need for open brain surgery by using a minimally-invasive procedure.

Related People

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech